FiercePharmaOriginal article
{"a":[{"_":"Aurinia settles with Teva, helping stave off potential Lupkynis generic until late 2036","$":{"href":"/pharma/aurinia-settles-teva-securing-market-exclusivity-lupkynis-until-late-2036","hreflang":"en"}}]}
Patent ExpiryLupkynisPositive
AI Analysis
Summary
Aurinia Pharmaceuticals settled a patent infringement case with Teva Pharmaceuticals, securing market exclusivity for Lupkynis until December 2036 and preventing generic competition. The settlement drove Aurinia's share price up 7%.
Outcome Details
Patent infringement settlement with Teva staves off generic competition until December 2036
Importance:7/10
Sentiment:
0.75
settlementpatentgeneric competitionmarket exclusivitylupus
Read the original article
Published by FiercePharma on August 20, 2026 10:53 AM